PROTEOME SCIENCES PLC — AGM Information 2026

May 14, 2026

National Storage Mechanism | Additional information

RNS Number : 3451E

Proteome Sciences PLC

14 May 2026

14 May 2026

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Annual General Meeting Statement

At the Company's Annual General Meeting ("AGM") being held today at 12.00 noon, the Chairman, Christopher Pearce, made the following statement:

"Good progress is being made in order levels in our services business and the recovery that we hoped for in TMT and reagent sales continues in the first half following the cuts in US NIH budgets and academic grants in 2025.

With the significant investment made in the business over the last 2 years, we believe we are well positioned to deliver substantial returns from our activities in the fast growing field of proteomics."

- Ends -

For further information:

Proteome Sciences plc
Christopher Pearce, Executive Chairman
Dr. Ian Pike, Chief Scientific Officer	Tel: +44 (0)20 7043 2116
Richard Dennis, Chief Commercial Officer
SP Angel Corporate Finance LLP  (Nominated Adviser & Broker)
David Hignell/Richard Morrison/Josh Ray  (Corporate Finance) Vadim Alexandre (Corporate Broking)	Tel: +44 (0) 20 3470 0470

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, with analysis using a range of depletion strategies in combination with TMTcalibrator™ providing access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Chemoproteomics using Solvent Shift  reveals the selectivity that drugs have to binding one or more proteins in the sample proteome.  Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

Further information on the Company can be found on its website at: https://www.proteomics.com/

The Company's LEI is 213800Q62ICXANKU2986.

This announcement should be read in its entirety. In particular, the information in the "Important Notices" section of the announcement should be read and understood.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGMEAPSLFFPKEEA